By M. Marin
American BriVision (OTC:ABVC) is a biopharma and medical device company developing therapies for a range of conditions focused on oncology/hematology, central nervous system (CNS) and ophthalmology. ABVC’s strategy is to find new products that have already shown efficacy in the Asia-Pacific region and introduce them to other international markets via licensing arrangements. The company is developing several clinical and business initiatives that management believes hold the potential for important milestones and catalysts.
American BriVision currently has six drugs and one medical device under development, with two lead assets that are in advanced stages of development in multiple programs. One important factor distinguishing ABVC’s products from those of many other drug candidates is that all of the company’s products are derived primarily from plants. ABVC believes that its plant-based therapies address these disorders without similar negative side effects. ABVC has a growing pipeline of assets.
ABV-1505 is one of ABVC’s two lead assets. The company has moved ABV-1505 through a phase II part I clinical trial for treatment in adult attention deficit hyperactivity disorder (ADHD), which was completed with a Clinical Study Report (CSR) issued on October 24, 2020. Moreover, given the observed improvements in patients enrolled in the trial, ABVC is expanding the active ingredient of ABV-1505, PDC-1421, into trials evaluating its efficacy in treating major depressive disorder (MDD) in cancer patients.
Vitargus, ABVC’s other primary asset, is a device that is used to replace vitreous in the eye during surgery. In 4Q20, ABVC issued a full CSR report of its Vitargus® first-in-human phase I clinical trial that found that Vitargus® was well-tolerated as a vitreous substitute without any apparent toxicity to ocular tissues and no indication of an increased safety risk. The enrolled patients also showed improvement in visual acuity compared to other vitreous substitutes.
We are optimistic about the chances of ABV-1505 and Vitargus receiving FDA approval and of the subsequent commercial demand of these treatment therapies. We estimate rapid growth for both once they are commercialized.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.